Skip to main content
Search
Main content
Neuron
Published

Alzheimer's disease pathology degrades an NMDA receptor-dependent spontaneous activity pattern in cortico-hippocampal circuits

Authors

Robert Ellingford, Samuel S Harris, Marten Kehring, Rikesh M Rajani, Francesca Kar Wey Lam, David Graykowski, Dorothea Bӧken, Lindsay A Welikovitch, Anita Khasnavis, Rhiannon Laban, Amanda Heslegrave, Umran Yaman, Anastasie Mate de Gerando, Suraya A Bond, Selina Wray, Dervis A Salih, David Dupret, Raymond J Dolan, David Klenerman, Henrik Zetterberg, Bradley T Hyman, Marc Aurel Busche

Abstract

Neuron. 2026 Mar 30:S0896-6273(26)00132-7. doi: 10.1016/j.neuron.2026.02.027. Online ahead of print.

ABSTRACT

Memory-based cognition relies on the integrity of cortico-hippocampal circuits, which are compromised in Alzheimer's disease (AD) as β-amyloid (Aβ) and tau accumulate. However, the mechanisms linking this pathology to circuit dysfunction remain unclear. In mouse models, using in vivo two-photon and Neuropixels recordings, we show that Aβ-tau pathology promotes both region- and layer-specific impairments, involving reduced burst firing in superficial cortical layers and CA1 and reduced mean firing of excitatory and inhibitory neurons in deep cortical layers and CA1. Exposure to Aβ primed the susceptibility of neuronal populations to tau-induced impairment. Combined Aβ-tau reduced synaptic NMDA receptor (NMDAR) density in both mouse and human tissue, while Aβ-tau co-reduction restored NMDARs and firing patterns and improved contextual memory. NMDAR antagonism in healthy mice phenocopied regional and laminar deficits. Our findings implicate synaptic NMDAR hypofunction as a reversible mechanism linking Aβ-tau synergy to cortico-hippocampal dysfunction in AD.

PMID:41916281 | DOI:10.1016/j.neuron.2026.02.027

UK DRI Authors

Rhiannon Laban

Research Technician, UK DRI Biomarker Factory

Research Technician, UK DRI Biomarker Factory

Rhiannon Laban
Amanda Heslegrave

Dr Amanda Heslegrave

Principal Research Fellow

Co-leading the UK DRI Biomarker Factory platform based at UK DRI at UCL

Dr Amanda Heslegrave
Selina Wray profile

Prof Selina Wray

UK DRI Affiliate Member - UCL

Professor of Molecular Neuroscience, UCL

Prof Selina Wray

Prof. David Klenerman

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Prof. David Klenerman
Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
Marc Aurel Busche profile picture

Dr Marc Aurel Busche

Group Leader

Understanding and repairing pathological neural circuits in Alzheimer's disease

Dr Marc Aurel Busche